Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited has announced a proposed capital raising involving the issue of up to 3,314,000 convertible notes and 25,000,000 new fully paid ordinary shares via a placement or similar structure. The proposed issuance, scheduled for 17 February 2026, is designed to strengthen the company’s balance sheet and provide funding flexibility for its therapeutic development programs, potentially diluting existing shareholders but supporting Neurizon’s ability to advance its pipeline and maintain its position in the competitive biotech market.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited, listed on the ASX under the code NUZ, operates in the biotechnology and therapeutics sector, focusing on the development of medical treatments. As a clinical-stage company, it raises capital periodically via equity and related securities to support its research, development, and commercialisation activities in pharmaceutical therapeutics.
Average Trading Volume: 817,788
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.